The present invention relates to a transdermal therapeutic system, comprising (a) a backing layer, (b) asolvent-based self-adhesive matrix layer containing rotigotine as active ingredient, and (c) a release liner, wherein the self-adhesive matrix layer has a coating weight of about 75-400 g/m2 and comprises a reservoir layer containing about 9-25 wt.-% rotigotine based on the weight of the reservoir layer, a kit comprising two transdermal therapeutic systems of the present invention as well as a method for the preparation of the transdermal therapeutic system of the present invention. In addition, the present invention relates to a transdermal therapeutic system comprising rotigotine as active ingredient for use in the treatment of patients suffering from Parkinson's disease, Parkinson's plus syndrome, depression, fibromyalgia and the restless-legs syndrome and for use in the treatment or prevention of dopaminergic neuron loss or cognitive disorders by transdermal administration of rotigotine once or twice weekly, wherein the transdermal therapeutic system comprises a backing layer, a solvent-based rotigotine containing self-adhesive matrix layer as well as a release liner and is adapted to allow for the transdermal administration of therapeutically effective amounts of rotigotine for at least 3 days.本發明關於經皮治療系統，其包含(a)背襯層，(b)含有羅替戈汀(rotigotine)作為活性成分之以溶劑為底質的自黏性基質層，及(c)剝離襯墊，其中該自黏性基質層之塗層重量為約75-400克/米2且包含含有約9-25重量%之羅替戈汀(按該儲集層之重量計)的儲集層，本發明關於包含本發明之二種經皮治療系統的套組以及用於製備本發明之經皮治療系統的方法。此外，本發明關於包含羅替戈汀作為活性成分之經皮治療系統於治療患有帕金森氏症、帕金森氏疊加症候群、抑鬱症、纖維肌痛(fibromyalgia)及不寧腿症候群(restless leg syndrome)之患者的用途，及包含羅替戈汀作為活性成分之經皮治療系統於治療或預防多巴胺能神經元損失或認知障礙之用途，其係經由每週一次或兩次經皮投服羅替戈汀來達成，其中該經皮治療系統包含背襯層、含有羅替戈汀之以溶劑為底質的自黏性基質層，以及剝離襯墊，且經過調整以容許經皮投服治療上有效量之羅替戈汀至少3天。
